Finance Watch: Public Companies Pursue All Options To Fund R&D, Launches

Immunome, Morphimmune Merge, Close $125m PIPE

Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.

Finance Watch Public Company
• Source: Alamy

The usual pattern of reporting positive clinical trial results or winning US Food and Drug Administration approval then launching a large follow-on public offering (FOPO) has become less common under current financial market conditions, but biopharmaceutical companies are finding plenty of alternative ways to fund their next crucial clinical trials or product launches.

More from Finance Watch

More from Financing